Medical Device and Healthcare Industry Trends — 2026-10-07

Top 5 Headlines Today

• FDA significantly eases oversight on wearables and AI devices, marking a shift in global digital health regulatory environments.
• Research shows that 75% of FDA-approved AI medical devices are concentrated in the field of radiology.
• OXOS Medical secures a $24 million contract from BARDA to develop next-generation portable X-ray systems.
• K-beauty companies accelerate business expansion beyond beauty devices into energy-based medical devices (EBD).
• Ministry of Food and Drug Safety (MFDS) prepares to implement new guidelines shortening innovative medical device approval periods to 240 days.

Key Corporate Trends (At Least 4 Items)

K-Beauty Companies (Including Manufacturers)

• What's Happening: A growing trend of expanding business domains from traditional cosmetics and beauty-device-centric business models into energy-based medical devices (EBD) and medical aesthetic solutions.
• Numbers: Specific sales figures have not been disclosed, but multiple beauty companies are including EBDs in their new product lineups.
• Implications: K-beauty brands' entry into the "medical beauty" market is evolving beyond simple marketing into a strategic expansion accompanied by actual medical device manufacturing licenses and approvals. This is directly tied to securing competitiveness in the global aesthetic medical market.

1 sources

koreatimes.co.kr

koreatimes.co.kr

OXOS Medical

• What's Happening: Signed a contract with the US Biomedical Advanced Research and Development Authority (BARDA) to develop next-generation portable X-ray systems.
• Numbers: Up to $24.4 million in BARDA funding, with a total project value of up to $48.8 million.
• Implications: Public funding support for developing next-generation imaging equipment is becoming more active, suggesting that portability and AI integration are emerging as core competitive advantages for future medical imaging equipment.

GigHz (Research Entity)

• What's Happening: Analyzed 1,430 FDA AI medical device approval records and released the distribution by field.
• Numbers: 75% of all AI medical device approvals are concentrated in the "Radiology" field.
• Implications: Growth in the AI diagnostics market is overly skewed toward a specific specialty (radiology), meaning the commercialization speed of AI in other specialties (pathology, dermatology, etc.) is relatively slow. This highlights the need for Korean AI startups (such as Lunit and Vuno) to diversify their portfolios.

MFDS, Policies, and Regulations (At Least 3 Items)

FDA Eases Regulations on Wearables and AI Devices

• Content: The FDA announced guidelines significantly easing regulatory oversight of wearable and AI-based digital health products. Expansion of exemption scopes for low-risk wellness software and wellness functions.
• Targets: Digital therapeutics (DTx), wearable sensors, and clinical decision support (CDS) tools.
• Implementation Timeline: Phased application starting early 2026 (guidelines announced in January 2026).
• Industry Impact: Entry barriers to the US market for Korean digital health companies are expected to lower. However, regulations on high-risk medical devices will remain, making product classification strategies increasingly important.

MFDS Innovative Medical Device '240-Day Fast-Track Approval' Guidelines

• Content: Finalized fast-track guidelines to process approval reviews for innovative medical devices within 240 days, a significant reduction compared to previous timelines.
• Targets: Domestic manufacturers and importers holding innovative medical device certifications.
• Implementation Timeline: Effective June 1, 2026 (recently reaffirmed and promoted).
• Industry Impact: Expected to accelerate market entry speeds for domestic startups and small-to-medium manufacturers. In particular, it enhances predictability for domestic approvals for companies gearing up for global expansion.

MFDS Abolishes Sales Suspension Grace Period for Medical Device GMP Regular Audit Violations

• Content: Strengthened regulations so that if in vitro diagnostic medical device manufacturing and quality control standards are violated prior to the expiration of the GMP validity period, import and sales will not be allowed during the previously granted "sales suspension grace period."
• Targets: In vitro diagnostic medical device manufacturers and importers.
• Implementation Timeline: Notified and implemented in March 2026.
• Industry Impact: Constant compliance with quality management systems (GMP) has become mandatory, and severe penalties—such as immediate sales bans—will be imposed for inadequate preparation for regular audits.

Digital Health & AI Healthcare (At Least 3 Items)

• FDA AI Medical Device Approval Status: Of 1,430 approvals, 75% are related to radiology. The remaining 25% are distributed across other fields such as pathology, ophthalmology, and cardiovascular. Data proves that the adoption of AI diagnostics in clinical settings is centered around imaging diagnostics.
• Stagnation in Digital Healthcare Investments: Global digital health venture capital investments plunged in the second quarter. In particular, investment contraction in the digital therapeutics (DTx) sector is striking. Startups lacking proven profitability face threats to their survival.
• Domestic Pharmaceutical Companies Entering Digital Health: Major pharmaceutical companies such as Daewoong Pharmaceutical and Dong-A ST are declaring digital health (telemedicine, digital therapeutics) as a future growth engine and pursuing aggressive investments.

Global MedTech Context

• FDA's Regulatory Easing Stance — Implications for the Korean Industry: Easier entry into the US market for low-risk digital health products expands opportunities for Korean wearable and app-based healthcare companies to target the North American market.
• Concentration of AI Diagnostics in Radiology — Implications for the Korean Industry: Korean AI diagnostic companies like Lunit and Vuno need to secure differentiated clinical data in specialties outside of radiology to gain an upper hand in global competition.
• OXOS's BARDA Contract Win — Implications for the Korean Industry: US government public procurement and R&D support programs (BARDA) can serve as crucial channels for Korean medical device companies to secure hospital deliveries and references within the US.

Investment, M&A, and IPO Trends

• Global Digital Health Investment Trends: Global digital health venture capital investments in the first half of 2026 decreased compared to the previous year. In particular, both the number of investment attraction deals and amounts in the DTx (digital therapeutics) sector showed a downward trend.
• Domestic Startup GiVita Secures Series A Funding: Digital healthcare startup GiVita successfully attracted 4.5 billion KRW in Series A investment, aimed at expanding pre-diabetes management services.

Today's Insight

The FDA's regulatory easing and AI diagnostics radiology concentration data demand "selection and concentration" from Korean medical device companies. Wearable and mild-condition management apps should exploit lowered FDA barriers to target early entry into the US market, while high-risk AI diagnostic devices must secure unmatched clinical evidence in specialties outside of radiology. Furthermore, the MFDS's 240-day fast-track approval and strengthened GMP are acting as dual axes simultaneously elevating the speed and quality of the domestic ecosystem.

This Week's Checkpoints

• Re-evaluation of product classifications for Korean export products is necessary following the FDA's new AI/wearable guidelines.
• Monitor the status of innovative medical device certification applications targeted for the MFDS 240-day fast-track approval.
• Verify whether domestic startups are successfully closing subsequent investment rounds amid the declining trend in global VC digital health investments.

Reader Action Items

• Practitioners: Precisely diagnose whether your digital health product falls under the FDA's "low-risk exemption" scope.
• Investors: Discover AI startups accumulating clinical data in specialties outside of radiology, such as pathology and cardiovascular fields.
• Founders: Pre-check the qualification requirements for "innovative medical device" certification to leverage the MFDS 240-day fast-track approval track.